UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report: August 2, 2006
Date of earliest event reported: August 2, 2006
PFIZER INC.
(Exact name of registrant as specified in its charter)
|
Delaware
|
1-3619
|
13-5315170
|
|
(State or other Jurisdiction of incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
|
10017
(Zip Code) |
Registrant's telephone number, including area code:
(212) 573-2323
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions:
[ ] Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
| Item 8.01 | Other Events |
| On August 2, 2006, Pfizer Inc. ("Pfizer") issued a press release announcing the decision of a panel of the U. S. Court of Appeals with respect to two patents relating to Lipitor. The information contained in the press release is deemed to be “filed” under the Securities Exchange Act of 1934 as Exhibit 99 to this report, and such press release is incorporated herein by reference. | |
| Item 9.01 Financial Statements and Exhibits |
| (d) Exhibits | ||
| Exhibit 99 | Press Release of Pfizer Inc. dated August 2, 2006 |
SIGNATURE
Under the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the authorized undersigned.
|
PFIZER INC.
|
||
|
By: /s/ Margaret M. Foran
Margaret M. Foran |
||
|
Title: Senior Vice President-Corporate
Governance, Associate General Counsel and Corporate Secretary |
||
| Dated: August 2, 2006 |
EXHIBIT INDEX
|
Exhibit No. |
Description |
| 99 | Press Release of Pfizer Inc. dated August 2, 2006. |